News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Cipla Ltd. Joins Challengers To Sanofi-Synthelabo’s Plavix Drug
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Cipla and its partner Watson Pharmaceuticals plan to seek US approval for a generic version of Sanofi-Synthelabo's blood-thinning drug Plavix, Cipla's chairman said on Monday.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
FDA
Approvals
Regulatory
MORE ON THIS TOPIC
Weight loss
Approvals in Hand, Lilly and Novo Obesity Pills Will Battle It Out on Hairline Differences
April 2, 2026
·
3 min read
·
Annalee Armstrong
Drug pricing
Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is Chilling
April 2, 2026
·
3 min read
·
Annalee Armstrong
Job Trends
Innovation Pressure Cooker: Tackling Drug Discovery’s Biggest Challenges
April 2, 2026
·
5 min read
·
Angela Gabriel
Layoffs
Layoffs at Novo’s Ex-Catalent Site Despite Signs of Turnaround, Continued Investment
April 1, 2026
·
2 min read
·
Nick Paul Taylor
